

Section 1: Identification**Product identifier** Cerenia Tablets**Other means of identification**

Synonyms CERENIA * Cerenia® Tablets * Cerenia (maropitant citrate) Tablets * Cerenia® Tablets for Dogs
* Maropitant Citrate Tablets

Recommended use of the chemical and restrictions on use**Recommended use** Veterinary product used as Anti-emetic**Restrictions on use** Not for human use**Details of manufacturer or importer**

Company Name (NZ) Zoetis New Zealand Limited
Level 4, 8 Mahuhu Crescent
Auckland Central
Auckland 1010, New Zealand

Telephone No. 0800 963 847 (Business Hours)

Emergency No. (National Poisons Centre) 0800 POISON (0800 764 766)

Emergency No. (Emergency Services) In an emergency dial 111

Section 2: Hazard identification**Classification of the hazardous chemical****Physical hazards** Not classified.

Health hazards Serious eye damage/eye irritation Category 1
Specific target organ toxicity following repeated exposure Category 2 (cardiovascular system, liver)

Environmental hazards Hazardous to the aquatic environment, acute hazard Category 2
Hazardous to the aquatic environment, long-term hazard Category 2

Label elements, including precautionary statements**Hazard symbol(s)**

Corrosion

Health
hazard

Environment

Signal word Danger

Hazard statement(s) Causes serious eye damage. May cause damage to organs (cardiovascular system, liver) through prolonged or repeated exposure. Toxic to aquatic life with long lasting effects.

Precautionary statement(s)

Prevention Do not breathe dust/fume/gas/mist/vapours/spray. Avoid release to the environment. Wear eye protection/face protection.

Response IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTRE/doctor. Collect spillage.

Storage Store away from incompatible materials.

Disposal Dispose of contents/container in accordance with local/regional/national/international regulations.

Other hazards which do not result in classification None.

Supplemental information

Drugs of this class have been associated with rare, but potentially serious cardiac events. These effects have not been observed from occupational exposures, however, those with preexisting cardiovascular illnesses may be at increased risk from exposure.

Section 3: Composition/information on ingredients**Mixture**

Identity of chemical ingredients	CAS number and other unique identifiers	Concentration of ingredients
Microcrystalline cellulose	9004-34-6	50 - 60
Maropitant citrate monohydrate	359875-09-5	23.2
Magnesium stearate	557-04-0	< 3

Section 4: First-aid measures**Description of necessary first aid measures**

Inhalation	Move to fresh air. For breathing difficulties, oxygen may be necessary. Call a physician if symptoms develop or persist.
Skin contact	Wash off with soap and plenty of water. Take off contaminated clothing and wash before reuse. If skin irritation occurs: Get medical advice/attention.
Eye contact	Immediately flush eyes with plenty of water for at least 15 minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Get medical attention immediately.
Ingestion	Call a physician or poison control centre immediately. Rinse mouth. Never give anything by mouth to a victim who is unconscious or is having convulsions. Do not induce vomiting without advice from poison control center.

Personal protection for first-aid responders	IF exposed or concerned: Get medical advice/attention. Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves. Wash contaminated clothing before reuse. For personal protection, see section 8 of the SDS. You should call The Poisons Information Centre if you feel that you may have been poisoned, burned or irritated by this product. The number is 13 1126 from anywhere in Australia (0800 764 766 in New Zealand) and is available at all times. Have this SDS with you when you call.
---	--

Symptoms caused by exposure	Severe eye irritation. Symptoms may include stinging, tearing, redness, swelling, and blurred vision. Permanent eye damage including blindness could result. Prolonged exposure may cause chronic effects. Individuals with cardiac conditions may be more susceptible to toxicity in cases of overexposure.
------------------------------------	--

Medical attention and special treatment	Provide general supportive measures and treat symptomatically. Symptoms may be delayed.
--	---

Section 5: Fire-fighting measures**Extinguishing media**

Suitable extinguishing media	Water fog. Foam. Dry chemical powder. Carbon dioxide (CO ₂).
Unsuitable extinguishing media	Do not use water jet as an extinguisher, as this will spread the fire.

Specific hazards arising from the chemical	During fire, gases hazardous to health may be formed.
---	---

Special protective equipment and precautions for fire fighters	Self-contained breathing apparatus and full protective clothing must be worn in case of fire.
---	---

Fire fighting equipment/instructions	Use water spray to cool unopened containers.
---	--

Hazchem code	None.
---------------------	-------

Hazards from combustion products	None.
---	-------

General fire hazards	No unusual fire or explosion hazards noted.
-----------------------------	---

Specific methods	Use standard firefighting procedures and consider the hazards of other involved materials.
-------------------------	--

Section 6: Accidental release measures**Personal precautions, protective equipment and emergency procedures**

For non-emergency personnel	Keep unnecessary personnel away.
------------------------------------	----------------------------------

For emergency responders	Wear appropriate protective equipment and clothing during clean-up. Ventilate the contaminated area. Keep unnecessary personnel away. ELIMINATE all ignition sources (no smoking, flares, sparks or flames in immediate area). Ensure adequate ventilation. Do not breathe dust. Avoid dust formation. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Avoid contact with eyes, skin, and clothing. Local authorities should be advised if significant spillages cannot be contained. Use personal protection recommended in Section 8 of the SDS.
Environmental precautions	Avoid release to the environment. Inform appropriate managerial or supervisory personnel of all environmental releases. Prevent further leakage or spillage if safe to do so. Avoid discharge into drains, water courses or onto the ground.
Methods and materials for containment and cleaning up	Eliminate all ignition sources (no smoking, flares, sparks, or flames in immediate area). Ground/bond container and equipment. Avoid dust formation. Ensure adequate ventilation. Prevent product from entering drains.
	Large Spills: Stop the flow of material, if this is without risk. Sweep up or vacuum up spillage and collect in suitable container for disposal. Clean contaminated surface thoroughly.
	Small Spills: Wipe up with a damp cloth and place in container for disposal. Clean surface thoroughly to remove residual contamination.
	Never return spills to original containers for re-use. For waste disposal, see section 13 of the SDS. Prevent release to the environment.

Section 7: Handling and storage

Precautions for safe handling	Do not handle, store or open near an open flame, sources of heat or sources of ignition. Protect material from direct sunlight. Avoid contact with eyes, skin, and clothing. Avoid prolonged exposure. When using, do not eat, drink or smoke. Wear appropriate personal protective equipment. Wash hands thoroughly after handling. Avoid release to the environment. Observe good industrial hygiene practices. Use with adequate ventilation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes.
Conditions for safe storage, including any incompatibilities	Store at 15-30°C (59-86°F). Keep away from heat, sparks and open flame. Store in a well-ventilated place. Keep away from food, drink and animal feeding stuffs. Store away from incompatible materials (see Section 10 of the SDS).

Section 8: Exposure controls/personal protection

Control parameters	Follow standard monitoring procedures.
---------------------------	--

Occupational exposure limits

Zoetis

Components	Type	Value
Maropitant citrate monohydrate (CAS 359875-09-5)	TWA	20 µg/m³

New Zealand. OELs (Workplace Exposure Standards and Biological Exposure Indices)

Components	Type	Value	Form
Magnesium stearate (CAS 557-04-0)	TWA	10 mg/m3	
Microcrystalline cellulose (CAS 9004-34-6)	TWA	10 mg/m3	Fiber.

US. ACGIH Threshold Limit Values (TLV)

Components	Type	Value	Form
Magnesium stearate (CAS 557-04-0)	TWA	3 mg/m3	Respirable fraction.
		10 mg/m3	Inhalable fraction.
Microcrystalline cellulose (CAS 9004-34-6)	TWA	10 mg/m3	

UK. OELs. Workplace Exposure Limits (WELs) (EH40/2005 (Fourth Edition 2020)), Table 1

Components	Type	Value	Form
Microcrystalline cellulose (CAS 9004-34-6)	STEL	20 mg/m3	Inhalable dust.
	TWA	4 mg/m3	Respirable dust.
		10 mg/m3	Inhalable dust.

Australia. National Workplace OELs (Workplace Exposure Standards for Airborne Contaminants, Appendix A)

Components	Type	Value	Form
Magnesium stearate (CAS 557-04-0)	TWA	10 mg/m3	Inhalable dust.
Microcrystalline cellulose (CAS 9004-34-6)	TWA	10 mg/m3	Inhalable fibers.
Biological limit values	No biological exposure limits noted for the ingredient(s).		
Control banding approach	Not available.		
Appropriate engineering controls	Good general ventilation (typically 10 air changes per hour) should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels to an acceptable level. General ventilation normally adequate. Provide eyewash station.		
Individual protection measures, for example personal protective equipment (PPE)			
Eye/face protection	Wear safety glasses or goggles if eye contact is possible. Chemical goggles are recommended.		
Skin protection			
Hand protection	Wear protective gloves. Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.		
Other	Wear suitable protective clothing. Use protective clothing (uniforms, lab coats, disposable coveralls, etc.) in both production and laboratory areas.		
Respiratory protection	No personal respiratory protective equipment normally required. If engineering controls do not maintain airborne concentrations below recommended exposure limits (where applicable) or to an acceptable level (in countries where exposure limits have not been established), an approved respirator must be worn. Respiratory protection should be provided in instances where exposure to dust, mists, aerosols or vapors are likely.		
Thermal hazards	Not applicable.		
Hygiene measures	Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants.		

Section 9: Physical and chemical properties

Appearance	tablet
Physical state	Solid.
Form	Solid.
Colour	Peach
Odour	Not available.
Odour threshold	Not available.
pH	Not available.
Melting point/freezing point	Not available.
Initial boiling point and boiling range	Not available.
Flash point	Not available.
Evaporation rate	Not available.
Flammability (solid, gas)	Not available.
Upper/lower flammability or explosive limits	
Explosive limit - lower (%)	Not available.
Explosive limit – upper (%)	Not available.
Vapour pressure	Not available.
Vapour density	Not available.
Relative density	Not available.
Solubility(ies)	
Solubility (water)	Not available.
Partition coefficient (n-octanol/water)	Not available.

Auto-ignition temperature	Not available.
Decomposition temperature	Not available.
Kinematic viscosity	Not available.
Other physical and chemical parameters	
Explosive properties	Not explosive.
Oxidising properties	Not oxidising.

Section 10: Stability and reactivity

Reactivity	The product is stable and non-reactive under normal conditions of use, storage and transport.
Chemical stability	Material is stable under normal conditions.
Possibility of hazardous reactions	No dangerous reaction known under conditions of normal use.
Conditions to avoid	Sunlight. Heat, flames and sparks. High temperatures. Contact with incompatible materials.
Incompatible materials	Strong oxidising agents. Fluorine.
Hazardous decomposition products	Irritating and/or toxic fumes and gases may be emitted upon the product's decomposition.

Section 11: Toxicological information

Information on likely routes of exposure

Inhalation	Prolonged inhalation may be harmful.
Skin contact	Prolonged skin contact may cause temporary irritation.
Maropitant citrate monohydrate	Species: Rabbit Severity: Non-irritating
Microcrystalline cellulose	Species: Rabbit Severity: Non-irritating
Eye contact	Causes serious eye damage.
Microcrystalline cellulose	Species: Rabbit Severity: Non-irritating
Maropitant citrate monohydrate	Species: Rabbit Severity: Severe

Ingestion May cause discomfort if swallowed.

Symptoms related to the physical, chemical and toxicological characteristics Severe eye irritation. Symptoms may include stinging, tearing, redness, swelling, and blurred vision. Permanent eye damage including blindness could result. Prolonged exposure may cause chronic effects.

Information on toxicological effects

Acute toxicity Not acutely toxic

Components	Species	Test Results
Magnesium stearate (CAS 557-04-0)		
Acute		
Inhalation		
LC50	Rat	> 2000 mg/m3
Oral		
LD50	Rat	> 2000 mg/kg
Maropitant citrate monohydrate (CAS 359875-09-5)		
Acute		
Dermal		
LD50	Rat	> 2000 mg/kg
Oral		
LDmin.	Rat	1000 mg/kg (Maropitant methanesulfonate salt)

Components	Species	Test Results
<u>Subchronic</u>		
Oral		
NOAEL	Dog	5 mg/kg/day, 3 months [Target organ(s): Cardiovascular system (Maropitant methanesulfonate salt)]
	Rat	5 mg/kg/day, 3 months [Target organ(s): Liver (Maropitant methanesulfonate salt)]
Microcrystalline cellulose (CAS 9004-34-6)		
<u>Acute</u>		
Dermal		
LD50	Rabbit	> 2000 mg/kg
Oral		
LD50	Rat	> 5000 mg/kg
Skin corrosion/irritation	Prolonged skin contact may cause temporary irritation.	
Corrosivity		
Maropitant citrate monohydrate	Species: Rabbit	Severity: Non-irritating
Serious eye damage/eye irritation	Causes serious eye damage.	
Eye contact		
Microcrystalline cellulose	Species: Rabbit	Severity: Non-irritating
Maropitant citrate monohydrate	Species: Rabbit	Severity: Severe
Respiratory irritation	Not available.	
Respiratory or skin sensitisation		
Respiratory sensitisation	Not a respiratory sensitiser.	
Skin sensitisation	This product is not expected to cause skin sensitisation.	
Skin Sensitisation		
Maropitant citrate monohydrate	GPMT	Species: Guinea Pig
	Severity: Negative	
Germ cell mutagenicity	No data available to indicate product or any components present at greater than 0.1% are mutagenic or genotoxic.	
Mutagenicity		
Maropitant citrate monohydrate	Result: Negative (In vitro, in vivo - Maropitant methanesulfonate salt)	
Carcinogenicity	Due to partial or complete lack of data the classification is not possible.	
ACGIH Carcinogens		
Magnesium stearate (CAS 557-04-0)	A4 Not classifiable as a human carcinogen.	
IARC Monographs. Overall Evaluation of Carcinogenicity		
Not listed.		
Reproductive toxicity	Based on available data, the classification criteria are not met.	
Developmental effects		
Maropitant citrate monohydrate	150 mg/kg/day Embryo / Fetal Development, Not teratogenic	
	Result: NOEL	
	Species: Rat	
Specific target organ toxicity - single exposure	Not classified.	
Specific target organ toxicity - repeated exposure	May cause damage to organs (cardiovascular system, liver) through prolonged or repeated exposure.	

Aspiration hazard	Not an aspiration hazard.
Narcotic effects	Due to lack of data the classification is not possible.
Chronic effects	Prolonged inhalation may be harmful. May cause damage to organs through prolonged or repeated exposure.
Further information	Drugs of this class have been associated with rare, but potentially serious cardiac events. These effects have not been observed from occupational exposures, however, those with preexisting cardiovascular illnesses may be at increased risk from exposure.

Section 12: Ecological information

Ecotoxicity Avoid release to the environment. Toxic to aquatic life with long lasting effects.

Components	Species		Test Results
Maropitant citrate monohydrate (CAS 359875-09-5)			
Aquatic			
Crustacea	IC50	Red Algae	0.23 mg/l, 7 days
	NOEC	Red Algae	0.082 mg/l, 7 days
	EC50	Daphnia magna (Water Flea)	0.6 mg/l, 1.25 hours
	LC50	Mysidopsis bahia (Mysid Shrimp)	0.68 mg/l, 48 hours
	NOEC	Daphnia magna (Water Flea)	0.31 mg/l, 1.25 hours
Fish		Mysidopsis bahia (Mysid Shrimp)	0.302 mg/l, 48 hours
	LC50	Cyprinodon variegatus (Sheepshead Minnow)	0.68 mg/l, 48 hours
	NOEC	Cyprinodon variegatus (Sheepshead Minnow)	0.302 mg/l, 48 hours

Persistence and degradability No data is available on the degradability of this product. In the environment, the active ingredient in this formulation is expected to degrade slowly.

Bioaccumulative potential See below

Partition coefficient

n-octanol / water (log Kow)

Maropitant citrate monohydrate 5.12, (+/- 0.01)

Mobility in soil No data available for this product. The following information is available for the individual ingredients.

Adsorption

Soil/Sediment Sorption - Log Koc

Maropitant citrate monohydrate 4.16, (estimated)

Other adverse effects No other adverse environmental effects (e.g. ozone depletion, photochemical ozone creation potential, endocrine disruption, global warming potential) are expected from this component.

Section 13: Disposal considerations

Disposal methods Avoid release to the environment. Do not discharge into drains, water courses or onto the ground. Dispose of contents/container in accordance with local/regional/national/international regulations. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Residual waste Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner.

Contaminated packaging Since emptied containers may retain product residue, follow label warnings even after container is emptied.

Special precautions to be taken during disposal Dispose in accordance with all applicable regulations.

Method of disposal that should not be used None known.

Section 14: Transport information

IATA


UN number	UN3077
UN proper shipping name	Environmentally Hazardous Substance, Solid, n.o.s (Maropitant citrate monohydrate)
Transport hazard class(es)	
Class	9
Subsidiary hazard	-
Packing group	III
Environmental hazards	Yes
Special precautions for user	Read safety instructions, SDS and emergency procedures before handling.

IMDG


UN number	UN3077
UN proper shipping name	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Maropitant citrate monohydrate), MARINE POLLUTANT (Maropitant citrate monohydrate)
Transport hazard class(es)	
Class	9
Subsidiary hazard	-
Packing group	III
Environmental hazards	
Marine pollutant	Yes
EmS	F-A, S-F
Special precautions for user	Read safety instructions, SDS and emergency procedures before handling.

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable.

IATA; IMDG



Marine pollutant



General information

IMDG Regulated Marine Pollutant. As of January 1, 2015, materials offered for transport that are classified for transportation only as Marine Pollutants and which are packaged in single or combination packagings containing a net quantity per single or inner packaging of 5 Liters or less for liquids or having a net mass per single or inner packaging of 5 kilograms or less for solids are NOT subject to ICAO/IATA, IMDG, or ADR transport regulations provided the general packaging requirements of those regulations are met. Refer to ICAO/IATA A197, IMDG 2.10.2.7, ADR SP 375. Please refer to the applicable dangerous goods regulations for additional information. Transport according to the requirements of the appropriate regulatory body.

Section 15: Regulatory information

Applicable regulations

Registered pursuant to the ACVM Act 1997, No. A9844.
See www.foodsafety.govt.nz for registration conditions.
Approved pursuant to the HSNO Act 1996, Code No. HSR100757.
See www.epa.govt.nz for approval controls.

New Zealand Inventory of Chemicals (NZIoC): Registration status

Magnesium stearate (CAS 557-04-0)

Does not have individual approval but may be used under an appropriate group standard

Section 16: Other information

Issue date	20-April-2022
Revision date	06-November-2024
Version No.	02
Key abbreviations or acronyms used	Not available.
Disclaimer	Zoetis Inc. believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time. The information in the sheet was written based on the best knowledge and experience currently available.
Revision information	This document has undergone significant changes and should be reviewed in its entirety.